Gail J. Roboz

基本信息

Career Trajectory

Bio

Funding awarded:
The VALIDATE study awarded by National Heart, Lung, & Blood Institute Principal Investigator 2022-2025
Pre-malignant mutation landscape and risk factors for progression to hematologic cancers awarded by National Cancer Institute Co-Investigator 2021-2026
Janssen Biopharma Agreement awarded by Janssen Biotech Inc. Principal Investigator 2020-2024
missing activity Co-Investigator 2020-2024

Research Interests

Papers共 676 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选

Reducing Clinical Trial Eligibility Barriers for Patients with MDS: an Icmds Position Statement

Uma Borate, Kelly Pugh, Allyson Waller, Rina Li Welkie, Ying Huang,Jan Philipp Bewersdorf,Maximilian Stahl,Amy E DeZern,Uwe Platzbecker,Mikkael A Sekeres,Andrew H Wei,Rena J Buckstein,Gail J Roboz,Michael R Savona,Sanam Loghavi,Robert P Hasserjian,Pierre Fenaux,David A Sallman,Christopher S Hourigan,Matteo Giovanni Della Porta, Stephen Nimer,Richard F Little,Valeria Santini,Fabio Efficace,Justin Taylor,Guillermo Garcia-Manero,Olatoyosi Odenike,Tae Kon Kim,Stephanie Halene,Rami S Komrokji,Elizabeth A Griffiths,Peter L Greenberg,Mina L Xu, Zhuoer Xie,Rafael Bejar, Guillermo F Sanz,Mrinal M Patnaik, Maria Figueroa,Hetty E Carraway,Omar Abdel-Wahab, Daniel Starczynowski,Eric Padron,Jacqueline Boultwood, Steven Gore, Naval G Daver,Jane E Churpek,Ravindra Majeti,John M Bennett,Alan F List,Andrew M Brunner,Amer M Zeidan

Bloodno. 13 (2025): 1369-1381

Cited0Views0WOSBibtex

Olutasidenib in Combination with Azacitidine Induces Durable Complete Remissions in Patients with Relapsed or Refractory Midh1 Acute Myeloid Leukemia: a Multicohort Open-Label Phase 1/2 Trial

Jorge E. Cortes,Gail J. Roboz,Maria R. Baer,Brian A. Jonas,Gary J. Schiller,Karen Yee,P. Brent Ferrell,Jay Yang,Eunice S. Wang,William G. Blum,Alice Mims, Hua Tian, Aaron Sheppard,Stéphane de Botton,Pau Montesinos,Antonio Curti,Justin M. Watts

Journal of Hematology & Oncologyno. 1 (2025): 1-13

Cited0Views0WOSBibtex

Deficit Accumulation Frailty Index (DAFI) and Treatment Tolerability in AML: Data from CALGB 11001 and 11002 (Alliance)

Catherine Lai,Minji Lee,Olivia Bobek,Jennifer Le-Rademacher,Sumithra Mandrekar,Gail J. Roboz,Geoffrey L Uy,Jeanne S. Mandelblatt,Heidi D. Klepin

Blood advancesno. 2 (2025): 398-401

Cited0Views0WOSBibtex

Standardization of Bone Marrow Reporting for Myelodysplastic Syndromes/Neoplasms on Behalf of the International Consortium for Myelodysplastic Syndromes/Neoplasms

Savanah D Gisriel, Fnu Aakash,John M Bennett,Robert P Hasserjian,Sanam Loghavi,Amy E DeZern,Valeria Santini,Michael R Savona,Andrew M Brunner,Rena Buckstein,Andrew H Wei, Matteo G Della Porta,Rami S Komrokji, Uma M Borate,Mikkael A Sekeres,Uwe Platzbecker,Pierre Fenaux,Gail J Roboz, Arjan van de Loosdrecht,Amer M Zeidan,Mina L Xu

Archives of pathology & laboratory medicine (2025)

Cited0Views0WOSBibtex

A Plain Language Summary of the ASCERTAIN Trial: Oral Decitabine and Cedazuridine Versus Intravenous Decitabine for MDS or CMML

Guillermo Garcia-Manero, James McCloskey,Elizabeth A Griffiths, Karen W L Yee,Amer M Zeidan,Aref Al-Kali, H Joachim Deeg,Mitchell Sabloff, Mary-Margaret Keating,Nancy Zhu, Nashat Y Gabrail,Salman Fazal, Joseph Maly,Olatoyosi Odenike,Amy E DeZern,Casey L O'Connell,Gail J Roboz,Lambert Busque,Rena Buckstein, Harshad Amin,Brian Leber,Aditi Shastri,Aram Oganesian, Harold N Keer,Mohammad Azab,Michael R Savona

Future oncology (London, England)no. 8 (2025): 929-941

Cited0Views0WOSBibtex

Oral Decitabine Cedazuridine with and Without Venetoclax in Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia: a Propensity Score–matched Study

Alex Bataller,Koji Sasaki,Samuel Urrutia, Guillermo Montalban-Bravo,Alexandre Bazinet, Kelly Chien,Danielle Hammond, Ian M Bouligny,Mahesh Swaminathan, Ghayas Issa, Nicholas Short,Naval Daver,Courtney D DiNardo,Tapan Kadia,Elias Jabbour,Farhad Ravandi,Gail J Roboz,Michael Savona,Elizabeth A Griffiths, James McCloskey,Olatoyosi Odenike,Aram Oganesian, Harold N Keer,Mohammad Azab, Hagop Kantarjian,Guillermo Garcia-Manero

Blood cancer journal（2025）

Cited0Views0WOSNATUREBibtex

Development of Oral Azacitidine with Cedazuridine for Myelodysplastic Syndrome (MDS) and Myeloproliferative Neoplasms (MPN) Including Chronic Myelomonocytic Leukemia (CMML) by Targeting Pharmacokinetic AUC Equivalence Vs Subcutaneous Azacitidine

Guillermo Garcia-Manero,James McCloskey,Bart L. Scott,Elizabeth A. Griffiths, Bonnie Kiner-Strachan,Gail J. Roboz, Janelle Meyer,Winny Chan,Yuri Sano,Aram Oganesian, Harold K. Keer,Michael R. Savona

Clinical Lymphoma Myeloma and Leukemia（2024）

Cited1Views0Bibtex

Blinded Ex-Vivo Testing in AML Reveals Differences Between Hypomethylating Agents when Combined with Venetoclax

Dunay Bach, Lía Buffa, Paula Scaglia, Agustina Garcia-Melani, Sharmaine Griffith-Baker, Tarek Ali Zaki,Gastón Soria,Gail J. Roboz

Bloodno. Supplement 1 (2024): 7492-7492

Cited0Views0Bibtex

Assessing Role of Comorbidities in Treatment Selection for Older Patients with Acute Myeloid Leukemia

Justin Grenet,Neela Easwar,Akriti G. Jain,Madelyn Burkart, Xiaoyue Ma,Paul Christos,Ellen K. Ritchie,Michael Samuel,Justin D. Kaner,Jonathan Canaani,Aaron D. Goldberg,Shira N. Dinner,Kendra L. Sweet,Gail J. Roboz,Pinkal Desai

Bloodno. Supplement 1 (2024): 2867-2867

Cited0Views0Bibtex

Author Statistics

Co-Author

Co-Institution

D-Core

合作者
学生
导师

No result temporarily, you can search similar Scholar with the same research interest

Data Disclaimer

The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn

Professor

Papers共 676 篇Author StatisticsCo-AuthorSimilar Experts